RxDoctor Payments Data

Patricia Russo Magno, MD

Critical Care Medicine · Providence, RINPI 1184609422

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $699 of the $795 with a category attached, or 87.9%. 10 manufacturers reported payments, led by AstraZeneca at 34.5% of the total. Reporting peaked in 2023 at $452 and has fallen 92.5% since, to $34 in 2025.

$795in general payments, 2019–2025

Across 36 payments — averaging $22.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$274
  • GSK$250
  • Sanofi-aventis U.S. LLC$97
  • Boehringer Ingelheim$45
  • Philips North America LLC$34
  • United Therapeutics Corporation$24
  • plus $72 from 4 others

What the payments were for

  • Food & beverage$69988%
  • Education$9712%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few critical care medicine providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$87,849
Medicare patients
545
Services billed
961

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter888$688,144
OfevNintedanib Esylate22$275,094
TezspireTezepelumab-Ekko22$118,707
Breo ElliptaFluticasone/Vilanterol218$106,463
Spiriva RespimatTiotropium Bromide102$75,607
Dupixent PenDupilumab18$65,157
Pirfenidone19$46,739
Dupixent SyringeDupilumab12$46,638
Breztri AerosphereBudesonide/Glycopyr/Formoterol61$38,790
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr52$31,783
Advair HfaFluticasone Propion/Salmeterol57$26,300
SymbicortBudesonide/Formoterol Fumarate91$26,094
Stiolto RespimatTiotropium Br/Olodaterol Hcl27$21,550
Spiriva HandihalerTiotropium Bromide30$19,365
Fluticasone-SalmeterolFluticasone Propion/Salmeterol120$16,668

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$250$857,1891,265 claims
Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat$45$372,251151 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$274$183,592174 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few critical care medicine providers in Rhode Islandon file to place this against a meaningful peer group, so we don't.

Other critical care medicine in Providence

See the full list for Rhode Island

Where these figures come from

Is this you, or does something look wrong? →